| ￥3300 | |
| Z05902-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized TNFSF12/TWEAK hFc Chimera, Human at 5μg/ml (100μl/well) on the plate can bind Biotinylated AntiTNFSF12 Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 49.62 kDa | ||||
| Apparent Molecular Weight | Due to enzyme lysis and glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS, 200mM L-arginine (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a well known multifunctional cytokine extensively distributed in cell types and tissues. Accumulating evidence has shown that TWEAK binding to the receptor factor-inducible 14 (Fn14) participates in diverse pathologic processes including cell proliferation and death, angiogenesis, carcinogenesis and inflammation. |
| Synonyms | APO3 ligand; APO3L; DR3LG; UNQ181/PRO207; TWEAK; MGC129581 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
